Revolution Medicines, Inc. Increase (Decrease) in Deferred Income Taxes
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Deferred Income Taxes of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-02-25
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for the quarter ending 2024-12-31 was $762.00K, a 1672.09% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for the quarter ending 2023-12-31 was $43.00K, a 65.04% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for the quarter ending 2022-12-31 was $123.00K.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for the quarter ending 2021-12-31 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for fiscal 2024 was $762.00K, a 80.51% decline from fiscal 2023.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for fiscal 2023 was $3.91M, a 833.17% increase from fiscal 2022.
- Revolution Medicines, Inc. increase (decrease) in deferred income taxes for fiscal 2022 was $419.00K.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $762.00K 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.91M 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $3.87M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $419.00K 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $296.00K 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | -$359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$359.00K derived: sum of 2 quarters · filed 2023-02-27 | -$341.00K derived: sum of 3 quarters · filed 2023-02-27 | $375.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $18.00K derived: sum of 2 quarters · filed 2021-11-10 | $734.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $734.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $716.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $4.37M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |